Featured Research

from universities, journals, and other organizations

Technology That Could Double The Effectiveness Of Cancer Drugs Studied At Yale

Date:
January 18, 2005
Source:
Yale University
Summary:
To identify the best treatment for recurrent ovarian cancer, researchers at Yale School of Medicine are studying a technology called the Yale apoptosis assay in combination with another technology called the ChemoFX assay, which could double the response rate to existing drugs.

New Haven, Conn. -- To identify the best treatment for recurrent ovarian cancer, researchers at Yale School of Medicine are studying a technology called the Yale apoptosis assay in combination with another technology called the ChemoFX assay, which could double the response rate to existing drugs.

Related Articles


In patients with recurrent ovarian cancer, it is often difficult to select an effective treatment because the tumor develops resistance to many drugs. Currently, physicians select a drug and must wait about six months to see whether it is effective on a particular patient.

"These two new assays will take the guesswork out of cancer treatment," said lead investigator, Gil Mor, M.D., associate professor of obstetrics and gynecology and reproductive sciences at Yale School of Medicine. "In patients with very limited time left to live, six months can feel like an eternity when they may have to start a whole new course of treatment if it proves ineffective."

Mor's lab developed the Yale apoptosis assay based on a biological principle that when a drug is effective, it will induce apoptosis (cell death) in the cancer cell. If the cancer cell is resistant to a drug, apoptosis does not occur.

Mor said, "The Yale apoptosis assay will determine whether a drug kills the tumor. The ChemoFX assay will determine whether a drug stops tumor growth. Used together, both assays will distinguish drugs that can stop the growth of the tumor and/or kill the tumor. This was not possible before."

"This test will help physicians predict whether a patient will respond to a specific drug, much like they test bacteria for sensitivity to antibiotics," Mor added.

The technology will be studied with various cancers, beginning with ovarian cancer. The clinical trial is a multi-center study for validation of the assays. Each assay will be evaluated independently and then in combination. The Yale research team partnered with Precision Therapeutics, Inc., (PTI) developers of the ChemoFX assay and is seeking patients from Yale and surrounding communities and from 10 other sites around the country. PTI exclusively licensed the Yale apoptosis assay from Yale. Recruitment for the study will be complete in June 2005, with results available about one year later. The Yale clinical trial is led by Thomas Rutherford, M.D., associate professor of gynecology at Yale School of Medicine.


Story Source:

The above story is based on materials provided by Yale University. Note: Materials may be edited for content and length.


Cite This Page:

Yale University. "Technology That Could Double The Effectiveness Of Cancer Drugs Studied At Yale." ScienceDaily. ScienceDaily, 18 January 2005. <www.sciencedaily.com/releases/2005/01/050110122824.htm>.
Yale University. (2005, January 18). Technology That Could Double The Effectiveness Of Cancer Drugs Studied At Yale. ScienceDaily. Retrieved November 25, 2014 from www.sciencedaily.com/releases/2005/01/050110122824.htm
Yale University. "Technology That Could Double The Effectiveness Of Cancer Drugs Studied At Yale." ScienceDaily. www.sciencedaily.com/releases/2005/01/050110122824.htm (accessed November 25, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Tuesday, November 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com
Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Newsy (Nov. 25, 2014) Need another reason to eat yogurt every day? Researchers now say it could reduce a person's risk of developing type 2 diabetes. Video provided by Newsy
Powered by NewsLook.com
Madagascar Working to Contain Plague Outbreak

Madagascar Working to Contain Plague Outbreak

AFP (Nov. 24, 2014) Madagascar said Monday it is trying to contain an outbreak of plague -- similar to the Black Death that swept Medieval Europe -- that has killed 40 people and is spreading to the capital Antananarivo. Duration: 00:42 Video provided by AFP
Powered by NewsLook.com
Are Female Bosses More Likely To Be Depressed?

Are Female Bosses More Likely To Be Depressed?

Newsy (Nov. 24, 2014) A new study links greater authority with increased depressive symptoms among women in the workplace. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins